ArticleAmerican journal of translational research2025
Exploring the potential of Buzhong Yiqi decoction in the treatment of membranous nephropathy: a comprehensive study combining bioinformatics, network pharmacology, and experimental validation.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveBuzhong Yiqi Decoction (BZYQ), a classic Chinese herbal formula, demonstrates clinical efficacy in treating membranous nephropathy (MN), yet its molecular mechanisms remains undefined. This study aims to uncover the therapeutic mechanisms of BZYQ against MN at the molecular level.
methodsBZYQ components/targets were retrieved from TCMSP and UniProtKB, while MN-related targets were obtained from GeneCards and GEO. Core targets were identified via Protein-Protein Interaction (PPI) analysis and machine learning (ML). Immune cell infiltration was analyzed using CIBERSORT, and diagnostic values were evaluated via Receiver Operating Characteristic (ROC) curves. Molecular docking validated interactions between core targets and BZYQ's active ingredients, with efficacy and mechanisms further verified in a cationic bovine serum albumin-induced mouse MN model.
resultsScreening identified
conclusionBZYQ emerges as a promising therapeutic for MN. Elucidating its anti-MN mechanisms provides a theoretical basis for clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.